SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Odefsey

GILD·GILEAD SCIENCES, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already marketed (FDA approved March 2016).
Why 3/10
Odefsey is an already-approved, marketed drug with no pending regulatory decision or pivotal readout in the next 12 months. It is a small part of Gilead's large, diversified pipeline and HIV portfolio (led by Biktarvy). Per the rubric, an approved drug with no imminent binary catalyst scores 3-5, and Odefsey's minor contribution to Gilead's overall value places it at the low end of that range.
Actionable Insight NEUTRAL

Odefsey has no upcoming binary catalyst; the next material event for the drug would be generic entry risk around 2033. Gilead's stock is driven by the broader HIV franchise (led by Biktarvy), oncology drug Trodelvy, and pipeline developments like the islatravir/lenacapavir once-weekly HIV regimen partnered with Merck. Watch Gilead's quarterly HIV sales breakdown and any Paragraph IV patent settlement updates for Odefsey.

Price Chart

Loading chart...

Executive Summary

Odefsey is a once-daily single-tablet HIV-1 regimen combining emtricitabine, rilpivirine, and tenofovir alafenamide, approved by the FDA in March 2016 and marketed by Gilead Sciences (GILD). It is a mature, commercially established product within Gilead's large HIV portfolio, which is dominated by the newer and much larger-selling Biktarvy ($4.1B in Q3 2026). Odefsey faces no imminent regulatory catalysts, and its patent-protected exclusivity is estimated to run until early 2033. For a Gilead investor, Odefsey is a stable but minor contributor to the company's overall HIV franchise revenue.

How It Works

Odefsey combines three antiviral drugs into one daily pill. Two of them (emtricitabine and tenofovir alafenamide) are NRTIs, which block HIV from copying its genetic material. The third (rilpivirine) is an NNRTI, which disables a protein HIV needs to replicate. Together they suppress the virus to undetectable levels in people with HIV.

Trial Status

Odefsey was approved by the FDA on March 1, 2016, based on Phase 3 clinical data demonstrating efficacy and safety as a complete regimen for HIV-1 treatment in treatment-naive adults and adolescents. The drug is widely marketed and prescribed, with a boxed warning about hepatitis B exacerbation upon discontinuation. The FDA label was most recently updated in December 2025.

The Two-Sided Case

▲ Bull Case4
Odefsey is a well-established, FDA-approved single-tablet HIV regimen with a decade of real-world use and safety data.
Gilead's HIV franchise is firing on all cylinders: Q3 2026 HIV sales rose 18% YoY to $6.249B, and Biktarvy reached an all-time high U.S. market share of 53%.
Patent protection extends to approximately 2033, providing a long runway of exclusivity against generic competition.
Gilead's overall base business grew 16% YoY in Q3 2026, the strongest in over a decade, with the company raising full-year guidance.
▼ Bear Case5
Odefsey is a mature product facing competition from newer, more convenient HIV regimens, particularly Gilead's own Biktarvy, which dominates the market.
A Paragraph IV patent challenge has been filed against Odefsey's patents, creating risk of earlier-than-expected generic entry.
MassHealth (Massachusetts Medicaid) began requiring prior authorization for Odefsey as of January 2026, potentially restricting access.
Gilead faces Medicare price negotiation on Biktarvy starting in 2028, which could pressure HIV franchise profitability even if Odefsey is not directly targeted.
Insider selling (all under 10b5-1 plans) and elevated short-sale volume relative to GILD's own history suggest some caution around the stock.

Upcoming Catalysts

  • No upcoming PDUFA or pivotal readout for Odefsey (already approved and marketed).
  • Patent expiry / generic entry risk around February 2033, subject to any Paragraph IV settlement.
  • Any Paragraph IV patent challenge settlement could bring earlier generic competition.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GILEAD SCIENCES, INC. 8-K GILD ·Originating report

Sources · 10

Hover a chip for the title
1 gilead.com2 accessdata.fda.gov3 dailymed.nlm.nih.gov4 drugpatentwatch.com5 pharsight.greyb.com6 investors.gilead.com7 gilead.com8 mass.gov9 drugs.com10 drugs.com